You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Simvastatin
Simvastatin is a HMG-CoA reductase inhibitor; decreases levels of low density lipoprotein. Has multiple biological effects including bone formation stimulation, inhibition of smooth muscle cell proliferation and migration, induction of ferroptosis, and anticancer and anti-inflammatory activity. Inactive lactone prodrug of simvastatin hydroxy acid, naturally bioactivated in vivo following oral administration.
Compound Libraries for Simvastatin
Technical Data for Simvastatin
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Simvastatin
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Simvastatin
The following data is based on the product molecular weight 418.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.75 mM||3.19 mL||15.93 mL||31.85 mL|
|3.75 mM||0.64 mL||3.19 mL||6.37 mL|
|7.5 mM||0.32 mL||1.59 mL||3.19 mL|
|37.5 mM||0.06 mL||0.32 mL||0.64 mL|
References for Simvastatin
References are publications that support the biological activity of the product.
Garrett et al (2001) STAT and bone formation. Curr.Pharm.Des. 7 715 PMID: 11405194
Kaushal et al (2003) Potential anticancer effects of STAT: fact or fiction? Endothelium 10 49 PMID: 12699077
White (1999) Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J.Clin.Pharmacol. 39 111 PMID: 11563401
Reinoso et al (2002) Preclinical pharmacokinetics of STAT. Methods Find.Exp.Clin.Pharmacol. 24 593 PMID: 12616706
If you know of a relevant reference for Simvastatin, please let us know.
View Related Products by Product Action
Keywords: Simvastatin, Simvastatin supplier, HMG-CoA, reductase, inhibitors, inhibits, Reductases, ferroptosis, hyperlipidemia, hypolipemic, statins, Reductase, Ferroptosis, 1965, Tocris Bioscience
4 Citations for Simvastatin
Citations are publications that use Tocris products. Selected citations for Simvastatin include:
Seto et al (2013) Acute SimV. inhibits K ATP channels of porcine coronary artery myocytes. Br J Pharmacol 8 e66404 PMID: 23799098
Vainio et al (2011) Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by STAT. Pharmacol Res Perspect 2 1176 PMID: 22202492
Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942
Seto et al (2007) Modulation by SimV. of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells. Oncotarget 151 987 PMID: 17558433
Do you know of a great paper that uses Simvastatin from Tocris? Please let us know.
Reviews for Simvastatin
Average Rating: 5 (Based on 1 Review.)
Have you used Simvastatin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
I used this drug to test the role of mevalonate pathway in joint integrity
It works well and the price is nice.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.